Successful Omalizumab Treatment of Rhinogenic Contact Point Headache Complicated by Severe Cedar Pollinosis: A Case Report.
children
omalizumab
pollinosis
rhinogenic contact point headache
seasonal allergic rhinitis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
24
12
2023
medline:
24
1
2024
pubmed:
24
1
2024
entrez:
24
1
2024
Statut:
epublish
Résumé
Headache is one of the most common neurological disorders in children. The most common headache in children is a primary headache, including migraine and tension-type headache, but note that secondary headaches should be differentiated as a cause of headache in pediatric patients. The management of cedar pollinosis in pediatric patients is important because it can cause quality-of-life deficits in addition to nasal and ocular symptoms. Omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, is approved in Japan as an add-on treatment option for severe cedar pollinosis, but few studies have investigated its real-world clinical efficacy in pediatric patients with seasonal allergic rhinitis. We report the case of a 15-year-old male patient with cedar pollinosis who suffered from uncontrolled naso-ocular symptoms, facial pain, and headache despite using histamine H
Identifiants
pubmed: 38264387
doi: 10.7759/cureus.51046
pmc: PMC10805559
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e51046Informations de copyright
Copyright © 2023, Suzaki et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.